A clinical SARS-CoV-2 Mpro inhibitor blocks replication of multiple enteroviruses and confers oral in vivo protection in animal models
PLOS Pathogens · 2026
DOI: 10.1371/journal.ppat.1014051 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Zhengyu Ye und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China. Hauptthemen laut MEDLINE: Virus Replication, Antiviral Agents, Enterovirus Infections, Enterovirus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Plan of China (CN), National Natural Science Foundation of China, National Key Research and Development Plan of China.
Abstract (Originalsprache)
Enteroviruses, which belong to the family Picornaviridae , cause hand, foot, and mouth disease (HFMD), respiratory symptoms, and severe neurological complications in children. Since vaccines cannot provide cross-protection against different serotypes of enteroviruses, the development of broad-spectrum anti-enteroviral drugs is imperative. The viral 3C protease (3C pro ), which is essential for polyprotein processing represents a validated target for therapeutic intervention. Importantly, enterovirus 3C pro shares conserved structural and catalytic features with coronavirus main protease (M pro , also known as 3C-like protease, 3CL pro ), providing a rationale for cross-target inhibitor repurposing. Through targeted screening of peptidomimetic protease inhibitors, a clinical-stage SARS-CoV-2 M pro inhibitor was identified as a potent inhibitor of enterovirus A71 (EV71) 3C pro . Bofutrelvir displayed nanomolar antiviral activity in multiple cell lines and demonstrated broad-spectrum efficacy against several enteroviruses including coxsackievirus B5, coxsackievirus A16 (CA16) and echovirus 11. In EV71 infected neonatal mice, intraperitoneal administration of bofutrelvir markedly reduced viral loads in brain, spinal cord, and muscle, alleviated clinical symptoms, and suppressed tissue inflammation. Oral administration of bofutrelvir also provided therapeutic benefits in neonatal mice models of both EV71 and CA16. Crystallographic analysis revealed that bofutrelvir binds in the conserved substrate-binding cleft of EV71 3C pro , elucidating its molecular mechanism of inhibition. These findings identify bofutrelvir as a broad-spectrum peptidomimetic 3C pro inhibitor with strong antiviral efficacy against enteroviruses and highlight its potential for repurposing as a promising antiviral candidate for the treatment of enteroviral infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
- University of the Chinese Academy of Sciences, Beijing China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.
- HuaWu Biotech, Wuhan, China.
- Hubei Jiangxia Laboratory, Wuhan, China.
ORCID-Profile: Lei-Ke Zhang
Förderung
- Key Research and Development Plan of China (CN)
- National Natural Science Foundation of China
- National Key Research and Development Plan of China
- Key R&D Program of Hubei Province
Zitieren
APA
Ye, Z., Dai, W., Zhang, S., Xiang, Y., Wang, J., Zhang, Y., Cao, W., Neyts, J., Li, Z., Feng, F., Xiao, G., Liu, H., Cao, J., & Zhang, L. K. (2026). A clinical SARS-CoV-2 Mpro inhibitor blocks replication of multiple enteroviruses and confers oral in vivo protection in animal models. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1014051
Vancouver
Ye Z, Dai W, Zhang S, Xiang Y, Wang J, Zhang Y, et al. A clinical SARS-CoV-2 Mpro inhibitor blocks replication of multiple enteroviruses and confers oral in vivo protection in animal models. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1014051
BibTeX
@article{Ye2026,
author = {Ye, Zhengyu and Dai, Wenhao and Zhang, Shaolin and Xiang, Yingchun and Wang, Jinlin and Zhang, Yumin and Cao, Wenyuan and Neyts, Johan and Li, Zuyi and Feng, Fan and Xiao, Gengfu and Liu, Hong and Cao, Junyuan and Zhang, Lei-Ke},
title = {A clinical SARS-CoV-2 Mpro inhibitor blocks replication of multiple enteroviruses and confers oral in vivo protection in animal models},
journal = {PLOS Pathogens},
year = {2026},
doi = {10.1371/journal.ppat.1014051}
}
EUVIMED